Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Moreau, Philippe [1 ]
Kumar, Shaji [2 ]
Boccia, Ralph [3 ]
Iida, Shinsuke [4 ]
Goldschmidt, Hartmut [5 ]
Cocks, Kim [6 ]
Zahlten-Kumeli, Anita [7 ]
Yucel, Emre [7 ]
Panjabi, Sumeet [7 ]
Dimopoulos, Meletios [8 ]
机构：
[1] Univ Hosp Hotel Dieu, Nantes, France
[2] Mayo Clin, Rochester, MN USA
[3] Ctr Canc & Blood Disorders, Bethesda, MD USA
[4] Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi, Japan
[5] Univ Hosp Heidelberg, Heidelberg, Germany
[6] KCStats Consultancy, Leeds, W Yorkshire, England
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
[8] Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷
关键词：
multiple myeloma; carfilzomib; once-weekly; patient-reported outcomes; quality of life;
D O I：
10.1016/j.clml.2018.07.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-138
引用
收藏
页码：S240 / S240
页数：1
相关论文
共 50 条
  • [21] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
    Bringhen, Sara
    Mina, Roberto
    Cafro, Anna Maria
    Liberati, Anna Marina
    Spada, Stefano
    Belotti, Angelo
    Gaidano, Gianluca
    Patriarca, Francesca
    Troia, Rossella
    Fanin, Renato
    De Paoli, Lorenzo
    Rossi, Giuseppe
    Lombardo, Alessandra
    Bertazzoni, Paola
    Palumbo, Antonio
    Sonneveld, Pieter
    Boccadoro, Mario
    LEUKEMIA, 2018, 32 (08) : 1803 - 1807
  • [22] Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies
    Leleu, Xavier
    Beksac, Meral
    Chou, Takaaki
    Dimopoulos, Meletios
    Yoon, Sung-Soo
    Prince, Henry Miles
    Pour, Ludek
    Shelekhova, Tatiana
    Chari, Ajai
    Khurana, Monica
    Obreja, Mihaela
    Qi, Ming
    Oriol, Albert
    Siegel, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S288 - S288
  • [23] Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study
    Sara Bringhen
    Roberto Mina
    Anna Maria Cafro
    Anna Marina Liberati
    Stefano Spada
    Angelo Belotti
    Gianluca Gaidano
    Francesca Patriarca
    Rossella Troia
    Renato Fanin
    Lorenzo De Paoli
    Giuseppe Rossi
    Alessandra Lombardo
    Paola Bertazzoni
    Antonio Palumbo
    Pieter Sonneveld
    Mario Boccadoro
    Leukemia, 2018, 32 : 1803 - 1807
  • [24] Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study (vol 19, pg 953, 2018)
    Moreau, P.
    Mateos, M-, V
    Berenson, J. R.
    LANCET ONCOLOGY, 2018, 19 (08): : E382 - E382
  • [25] Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
    Richardson, Paul G.
    Baz, Rachid
    Wang, Michael
    Jakubowiak, Andrzej J.
    Laubach, Jacob P.
    Harvey, R. Donald
    Talpaz, Moshe
    Berg, Deborah
    Liu, Guohui
    Yu, Jiang
    Gupta, Neeraj
    Di Bacco, Alessandra
    Hui, Ai-Min
    Lonial, Sagar
    BLOOD, 2014, 124 (07) : 1038 - 1046
  • [26] Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and ARROW Trials
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Iida, Shinsuke
    Huang, Shang-Yi
    Takezako, Naoki
    Chng, Wee Joo
    Zahlten-Kumeli, Anita
    Sersch, Martina A.
    Li, Julia
    Huang, Mei
    Lee, Jae Hoon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (04) : 466 - 473
  • [27] Comparative Efficacy and Safety of Once Versus Twice Weekly Carfilzomib Based Therapies in Relapsed Refractory Multiple Myeloma-a Systematic Review
    Rehman, Saif Ur
    Sharif, Saad
    Batool, Syeda Sabeeka
    Bajwa, Hamza
    Farooqui, Arafat Ali Ali
    Ahmed, Zahoor
    Anjum, Ahmad
    Bin Farooq, Talha
    Mukhtar, Samana
    Chaudhary, Sibgha Gull
    Tariq, Muhammad Junaid
    Syed, Tariq Iqtidar Sadiq
    Abdullah, Syed Maaz
    Faisal, Muhammad Salman
    Anwer, Faiz
    BLOOD, 2019, 134
  • [28] Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.
    Leleu, Xavier
    Beksac, Meral
    Chou, Takaaki
    Dimopoulos, Meletios A.
    Yoon, Sung-Soo
    Prince, H. Miles
    Pour, Ludek
    Shelekhova, Tatiana
    Chari, Ajai
    Khurana, Monica
    Obreja, Mihaela
    Qi, Ming
    Oriol, Albert
    Siegel, David Samuel DiCapua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 ARROW study
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Kumar, Shaji
    Rosenbaum, Cara
    Huang, Mei
    Goldrick, Amanda
    Blaedel, Julie
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E31 - E32
  • [30] Safety and Efficacy of Once-Weekly Carfilzomib (K) Dosing in Frail Patients (pts): A Subgroup Analysis from the Phase 3 ARROW Study
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Kumar, Shaji
    Rosenbaum, Cara
    Huang, Mei
    Goldrick, Amanda
    Blaedel, Julie
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S320 - S321
12345